Vaccine composition
A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide of H. influenzae b not adsorbed onto an aluminum adjuvant salt, and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, a conjugate of the capsular polysaccharide of H. influenzae b, and a conjugate of a capsular polysaccharide of N. meningitidis type A or C (or both). Furthermore, a multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide of H. influenzae b.
1. A multivalent immunogenic composition comprising the following components:
(a) killed whole-cell Bordetella pertussis,
(b) tetanus toxoid,
(c) diphtheria toxoid,
(d) Hepatitis B surface antigen,
(e) a conjugate of a carrier protein and the capsular polysaccharide of Haemophilus influenzae type B and
(f) one or more conjugates of a carrier protein and the capsular polysaccharide of a bacterium selected from the group consisting of Neisseria meningitidis type A and N. meningitidis type C.
2. The multivalent immunogenic composition of claim 1 , wherein the composition further comprises one or more conjugates of a carrier protein and the capsular polysaccharide of a bacterium selected from the group consisting of Neisseria meningitidis type Y and N. meningitidis type W.
3. The multivalent immunogenic composition of claim 1 , wherein the capsular polysaccharide of said Haemophilus influenzae type B is conjugated to a carrier protein selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRM197, outer membrane protein complex (OMPC) of N. meningitidis , and protein D of H. influenzae.
4. The multivalent immunogenic composition of claim 1 , wherein the capsular polysaccharide of said N. meningitidis is conjugated to a carrier protein selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRM197, outer membrane protein complex (OMPC) of N. meningitidis , and protein D of H. influenzae.
5. The multivalent immunogenic composition of claim 1 , wherein the composition further comprises killed, attenuated Hepatitis A virus.
6. The multivalent immunogenic composition of claim 1 , wherein the composition further comprises inactivated polio virus.
7. The multivalent immunogenic composition of claim 1 , wherein the composition comprises an adjuvant.
8. The multivalent immunogenic composition of claim 7 , wherein the adjuvant is aluminium salt.
9. A method of immunizing a mammalian host, the method comprising administering to the host an immunogenic dose of the multivalent immunogenic composition of claim 1 .
10. A method of making the multivalent immunogenic composition of claim 1 comprising the step of mixing together the components (a), (b), (c), (d), (e) and (f).